NCT06256536View on ClinicalTrials.gov

A Study of GZR18 Injection in Chinese Obese/Overweight Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

October 22, 2023

Study Completion Date

October 22, 2023

Conditions
ObesityOverweight
Interventions
DRUG

GZR18

0.6 mg-30 mg

OTHER

Placebo

administered the same volume as GZR18

Trial Locations (1)

Unknown

Gan & Lee Pharmaceuticals Co., Ltd, Beijing

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY